AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04967729 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Device: Butterfly iQ
Description: The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
Study NCT05373199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euglycemic clamp with BC Combo THDB0207
Description: Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
Study NCT05373199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Euglycemic clamp with Lantus®
Description: Administration of a single dose of Lantus® during an euglycemic clamp procedure.
Study NCT05373199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Euglycemic clamp with Humalog®
Description: Administration of a single dose of Humalog® during an euglycemic clamp procedure.
Study NCT04997863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sericin hydrogel sheet impregnated with EBN extract
Description: Sericin hydrogel sheet impregnated with EBN extract will be used as a primary dressing for preventing scar development at one-half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
Study NCT04997863 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo hydrogel sheet
Description: Placebo hydrogel sheet will be used as a primary dressing for preventing scar development at another half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
Study NCT06259097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 25 mcg vaginally every 6 hours
Study NCT06259097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitocin
Description: 3-6 mL intravenously every hour
Study NCT05856851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: See arm/group descriptions.
Study NCT05346809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab in IV form 10 mg/kg doses
Study NCT05346809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Procedures
Description: Standard procedures (standard of care) for transplant
Study NCT04628988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90011
Description: Capsule
Study NCT04628988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Tablet
Study NCT04628988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Tablet
Study NCT05553184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate 12 micrograms Inhalation Powder
Description: At time 60 minutes, a total of 48 micrograms will be inhaled within 3 minutes: 4 inhalations of 12 micrograms of fumarate formoterol (Oxeze® Turbuhaler®).
Study NCT05553184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinic Acid 50 MG Oral Tablet
Description: a total dose of 1050 MG will be ingested. From time 0 to 180 minutes, doses of 150 MG will be repeated every 30 minutes.
Study NCT05553184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute Cold Exposure
Description: Participants will be fitted with a liquid-conditioned tube suit. The liquid-conditioned tube suit will be perfused with 18°C water using a temperature- and flow-controlled circulation bath from time 0 to 180 min.
Study NCT05553184 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography (PET)
Description: PET imaging using C11-palmitate (time 90), C11-acetate (time 120) and F18-Fluorodeoxyglucose (FDG) (time 150)
Study NCT05553184 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: PET imaging using C11-palmitate (time 90), C11-acetate (time 120) and F18-Fluorodeoxyglucose (FDG) (time 150)
Study NCT05553184 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Indirect calorimetry
Description: will be repeated every hour, for 20 minutes, using Vmax29n.
Study NCT05553184 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry
Description: will be repeated every hour, for 20 minutes, using Vmax29n.
Study NCT05553184 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: dual-energy x-ray absorptiometry (DEXA scan)
Description: Whole body scan
Study NCT05553184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: After local anesthesia with 2% xylocaine without epinephrine, 100-200 mg of subcutaneous adipose tissue will be sampled by needle (14G) biopsy
Study NCT05553184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: After local anesthesia with 2% xylocaine without epinephrine, 100-200 mg of subcutaneous adipose tissue will be sampled by needle (14G) biopsy
Study NCT05553184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: iv lines
Description: for stable tracer perfusion and blood sampling
Study NCT05553184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iv lines
Description: for stable tracer perfusion and blood sampling
Study NCT05553184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electromyogram (EMG)
Description: Surface electrodes will be used to measure skeletal muscle activity and shivering intensity
Study NCT05876338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRCaSSM
Description: The intervention group will receive face-to-face training, giving patient education booklet and telephone counseling based on the symptom management model. After the training, it is planned to provide telephone counseling for a total of 6 times, once every 2 weeks for 3 months.
Study NCT05571020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mat pilates
Description: Both groups adapted for their rides by not participating in a different exercise and meal. In the study, they were not found in any store in the control groups. In the Mat-Pates Group, information about the 5 key elements of the study and pilates team, perspective (-neck-shoulder-waist-abdominal placement), lumbopel stabilization, scapular stabilization, review and information was covered. Then, in the study groups, it was purchased from groups of 5-6 people at most for one hour a day. In order to participate in all these application activities, he continues his life without participating in any evaluation.
Study NCT05286216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: effectiveness of education
Description: The education program will be prepared using power point presentations within the relevant scientific literature. The education program is planned to be given to each group as 1 session on 2 different days, between 09:30 and 13:00. Day 1 module 1; Module 2 will be shared on the 2nd day and all patients in the experimental group will participate in the education program. During and after the education, individuals will be provided with the opportunity to ask questions. In addition, after the education, the researcher's phone will be given and counseling will be provided by phone. The duration and subject of the telephone conversations will be recorded by the researcher.~In order to evaluate the training, all patients will be invited to the hospital on the day of the control at the end of 12 and 24 weeks, and evaluations will be made again with data collection tools.
Study NCT06190431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Learning the use of an in-exsufflation device with the guidance of a physiotherapist
Description: Learning to use an in-exsufflation device with the guidance of a physiotherapist
Study NCT06190431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Using the coaching mode
Description: Learning the use of an in-exsufflation device using a coaching mode (playful visual stimulation) in addition to guidance of a physiotherapist
Study NCT04064918 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Netarsudil 0.02% QD
Description: This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
Study NCT05651802 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic cranial irradiation
Description: Prophylactic cranial irradiation (PCI) is actually a habitual statement. It is a technique used to eliminate tiny metastatic lesions that have already existed in the brain, but can not be found by brain MRI and other inspection methods.
Study NCT05651802 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic radiotherapy
Description: Thoracic radiotherapy is a local treatment of tumors located in the chest using ionizing radiation.
Study NCT05651802 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: Thoracic radiotherapy is a local treatment of tumors located in the chest using ionizing radiation.
Study NCT05651802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy is the abbreviation of chemical drug therapy. It is a treatment method that uses chemical drugs to prevent the proliferation, invasion and metastasis of cancer cells, and finally kill cancer cells.
Study NCT05651802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy is the abbreviation of chemical drug therapy. It is a treatment method that uses chemical drugs to prevent the proliferation, invasion and metastasis of cancer cells, and finally kill cancer cells.
Study NCT05804357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion
Study NCT05804357 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: It is an approach that is combined with diaphragmatic breathing, activating the passive-active musculoskeletal and neural systems. In this approach, transversus abdominis and multifudus muscles are activated as deep core muscles.
Study NCT04507347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC041266
Description: TRC041266 sachet 1500 mg strengths
Study NCT04507347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TRC041266 sachet 1500 mg matching placebo
Study NCT06121778 — intervention group
Intervention type: OTHER
Intervention: Home
Description: There is no intervention but evaluations of elderly persons living at home will be conducted every three years and for the next 12 years. If some people leave the home, as far as possible, the reason will be asked.
Study NCT01427816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCT-0809
Study NCT01427816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06257563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isle of TEND Intervention
Description: The Isle of TEND is an interactive videogame platform in which users navigate to different modules on a virtual island. The modules aim to create a pleasant, shared and error-free experience for persons with dementia and their caregivers.
Study NCT05803122 — intervention group
Intervention type: OTHER
Intervention: Uniform Data Set (UDS) neuropsychological battery
Description: Uniform Data Set (UDS) neuropsychological battery was administered to patients with Mild Cognitive Impairment (MCI) and patients with Alzheimer's Disease
Study NCT05534776 — intervention group
Intervention type: OTHER
Intervention: Investigator Global Assessments (IGAs)
Description: 5-Point scale from 0-4 to score the severity of pemphigus, where 0=clear, 1=almost clear, 2=mild, 3=moderate and 4=severe.
Study NCT04766996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided mindfulness exercises
Description: Guided Meditation twice daily
Study NCT04766996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-administered aromatherapy
Description: Self-administered aromatherapy every 6 hours and at bedtime
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baby aspirin
Description: Baby aspirin 81mg: Twice daily for 6 weeks after surgery
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol/Acetaminophen
Description: Tylenol/Acetaminophen 1000mg: Pre-operative one dose; Every 8 hours for three weeks after surgery
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 25mg:~Twice a day for two weeks before surgery; Pre-operative 25-100 mg; Twice a day for two weeks after surgery
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5mg: Daily for three weeks after surgery
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5mg:~Twice a day, with food, for two weeks before surgery; Twice a day, with food, for two weeks after surgery
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilosec
Description: Prilosec 20mg:~Daily for two weeks before surgery; Daily for for two weeks after surgery
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Rescue pain medicine Tramadol 50mg up to three times a day as needed will be provided for rescue pain
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voltaren
Description: Voltaren 1% topical arthritis gel up to 4 times daily pre-operative only
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofran
Description: Zofran 4 mg pre-operative
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pepcid
Description: Pepcid 20 mg pre-operative
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reglan
Description: Reglan 10 mg pre-operative
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Versed
Description: Versed 2 mg pre-operative
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine (preservative free) height based dosing for subarachnoid block intraoperatively
Study NCT05236244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: İntervention group
Description: Diaphragmatic Breathing Exercises
Study NCT05282420 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection of Ranibizumab
Description: intravitreal injection of Anti-VEGF Ranibizumab (Lucentis®; manufactured in the United States by Genentech/Roche)
Study NCT05282420 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection of Aflipercept
Description: intravitreal injection of Anti-VEGF Aflibercept (Eylea®; manufactured in the United States)
Study NCT05282420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab
Study NCT05282420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflipercept
Study NCT04088591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid 500Mg/Ml Inj
Description: Ascorbic acid 200mg/kg/day administered upon suspicion or confirmation of sepsis every 6 hours for a total duration of 96 hours
Study NCT04088591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose in Water
Description: 50 ml of 5% dextrose in water every 6 hours for a total duration of 96 hours
Study NCT05510284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Doula-coordinated, midwife-delivered postpartum care
Description: A doula will coordinate all postpartum care and provide support to the participant. A midwife will be available on-site in the NICU to provide postpartum care.
Study NCT04687371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive vestibular exercise
Description: To assess effects of proprioceptive vestibular exercises training in patients with peripheral vestibular hypofunctions
Study NCT04687371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard vestibular rehabilitation exercises
Description: To assess effects of standard vestibular rehabilitation exercises in patients with peripheral vestibular hypofunctions
Study NCT04687371 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Controlled
Description: First and last measurement will be taken. There will be no intervention. study will include 9 patients.
Study NCT06526052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Program
Description: Online, coached mindfulness training program
Study NCT06526052 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Remote meetings with a supportive coach
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 10-125 mcg/kg/min intraoperative
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ancef
Description: Ancef 2-3 gm weight-based dosing intraoperative
Study NCT05547308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D myoelectric prosthetic device
Description: All subjects will use the 3D Prosthetic device and complete a variety of quality of life questionnaires.
Study NCT04064918 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Timolol maleate 0.5% BID
Description: This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
Study NCT03905902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC/OvCa
Description: activated autologous dendritic cells
Study NCT03905902 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DCVAC/OvCa
Description: activated autologous dendritic cells
Study NCT03905902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC/OvCa placebo
Description: placebo for activated autologous cells
Study NCT03905902 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DCVAC/OvCa placebo
Description: placebo for activated autologous cells
Study NCT05254327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMX-001
Description: Loading dose of 28 mg per subject, followed by maintenance doses of 14 mg per subject twice per week.
Study NCT05387668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-23339
Description: Administered orally as a tablet.
Study NCT05387668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally as a tablet.
Study NCT04969692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: warming to increase local skin (puncture site) temperature
Description: According to the group of participants, investigator applies the warmer to the hands and wrists of the participants, makes a local temperature of 40℃ gradually, and maintains it for about 10 minutes in warming group (which is divided in to warming-palpation (WP) and warming-US (WU) group).
Study NCT06085313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAI
Description: Web App-based information and coaching/support program for cancer pain management with additional components for the individual optimization functionality
Study NCT06085313 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAPA
Description: Web App-based information and coaching/support program for cancer pain management
Study NCT05629468 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: antibiotic
Study NCT05629468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: antibiotic
Study NCT05629468 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Probiotic Formula
Description: probiotics
Study NCT05629468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Formula
Description: probiotics
Study NCT05629468 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Benzoyl Peroxide 4 % Topical Cream
Description: topical cream
Study NCT05629468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl Peroxide 4 % Topical Cream
Description: topical cream
Study NCT05629468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl Peroxide 4 % Topical Cream
Description: topical cream